Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms
Open Access
- 1 May 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (5) , 775-778
Abstract
Anticancer drugs targeting angiogenesis act either directly on vascular endothelial growth factor (VEGF) receptors (VEGF inhibitors) or VEGF-mediated intracellular processes (tyrosine kinase inhibitors) or indirectly through downstream VEGF signaling within broader processes (mammalian target of rapamycin inhibitors and multiprotein kinase inhibitors). Although VEGF blockade may be implicated in arterial wall injuries, the literature on the association between antiangiogenic drugs and artery dissections or aneurysms is scant, comprising only a few case reports and 1 pharmacovigilance study conducted in Japan.1 The present study evaluated the association between all antiangiogenic drugs and dissections or aneurysms occurring in all arteries.Keywords
This publication has 7 references indexed in Scilit:
- Short-Term Risk of Aortoiliac Aneurysm or Dissection Associated With Fluoroquinolone UseJACC, 2019
- Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report DatabaseCirculation, 2017
- Pharmacoepidemiology and Drug Safety2016
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculationAnnals of Oncology, 2007
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionNature Reviews Cancer, 2007
- A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactionsPharmacoepidemiology and Drug Safety, 2002
- Effect of Vasa Vasorum Flow on Structure and Function of the Aorta in Experimental AnimalsCirculation, 1995